Herbal compound may cut liver cancer risk in High-Risk hepatitis b patients
NCT ID NCT07481032
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a traditional Chinese medicine called Biejia-Ruangan compound to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (based on a special score) will be randomly assigned to receive either the herbal compound or a placebo, plus their usual antiviral drugs. The main goal is to see if fewer liver cancers occur after 96 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Biejia-Ruangan compound (a traditional Chinese medicine formula)
- What this could lead to
- If it works, this could provide a new way to reduce liver cancer risk in people with hepatitis B-related cirrhosis.
- What could go wrong
- This is an early-stage trial with no phase designation, and the compound is a traditional Chinese medicine with limited prior evidence. The results may not show a clear benefit, and side effects are not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Can a diabetes drug help fight liver cancer? a trial puts it to the test